Search Within

Hiroki Sato

Formats
  1. Journal Article (5)
  2. Meeting Abstract (5)
Groups
  1. Department of Medicine (9)
  2. Department of Pathology and Laboratory Medicine (9)
  3. GSK Faculty (9)
  4. Human Oncology and Pathogenesis Program (9)
  5. Solid Tumor Oncology Division (9)
  6. Thoracic Oncology (9)

More Groups

People
  1. Marc Ladanyi (9)
  2. Adam Schoenfeld (6)
  3. Gregory Riely (6)
  4. Romel Somwar (6)
  5. Daisuke Kubota (5)
  6. Michael Offin (5)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (2)
  4. 2020 (3)
  5. 2019 (3)
Publications
  1. Journal of Thoracic Oncology (3)
  2. Cancer Research (2)
  3. Clinical Cancer Research (2)
  4. JCO Precision Oncology (1)
  5. Journal of Clinical Oncology (1)
  6. Oncogene (1)
Publishers
  1. American Association for Cancer Research (4)
  2. Elsevier Inc. (3)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (1)

Results (10)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK
    Journal Article

    Sato, H.; Ito, T.; Hayashi, T.; Kitano, S.; Erdjument-Bromage, H.; Bott, M. J.; Toyooka, S.; Zauderer, M.; Ladanyi, M.
    Oncogene (2024)

    Fulltext@MSK | Save
  • SRC family kinase inhibition targets YES1 and YAP1 as primary drivers of lung cancer and as mediators of acquired resistance to ALK and epidermal growth factor receptor inhibitors
    Journal Article

    Sato, H.; Kubota, D.; Qiao, H.; Jungbluth, A.; Rekhtman, N.; Schoenfeld, A. J.; Yu, H. A.; Riely, G. J.; Toyooka, S.; Lovly, C. M.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion positive lung cancers
    Meeting Abstract

    Iyer, S. R.; Odintsov, I.; Schoenfeld, A. J.; Sato, H.; Siau, E.; Drilon, A.; Riely, G. J.; Somwar, R.; Ladanyi, M.; Davare, M. A.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Allele-specific role of ERBB2 in the oncogenic function of EGFR L861Q in EGFR-mutant lung cancers
    Journal Article

    Sato, H.; Offin, M.; Kubota, D.; Yu, H. A.; Wilhelm, C.; Toyooka, S.; Somwar, R.; Kris, M. G.; Ladanyi, M.
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs)
    Meeting Abstract

    Sato, H.; Kubota, D.; Paik, P. K.; Qiao, H.; Jungbluth, A. A.; Rekhtman, N.; Schoenfeld, A. J.; Yu, H. A.; Riely, G. J.; Lovly, C. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer
    Journal Article

    Schoenfeld, A. J.; Chan, J. M.; Kubota, D.; Sato, H.; Rizvi, H.; Daneshbod, Y.; Chang, J. C.; Paik, P. K.; Offin, M.; Arcila, M. E.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • MAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusions
    Journal Article

    Sato, H.; Schoenfeld, A. J.; Siau, E.; Lu, Y. C.; Tai, H.; Suzawa, K.; Kubota, D.; Lui, A. J. W.; Qeriqi, B.; Mattar, M.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • A novel activating MAP2K1 in-frame deletion mediates acquired resistance to ROS1 TKIs in a patient with ROS1 fusion-positive NSCLC
    Meeting Abstract

    Sato, H.; Schoenfeld, A.; Siau, E.; Suzawa, K.; Yue, C.; Offin, M.; Drilon, A.; Davare, M.; Riely, G.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Generation and characterization of novel preclinical disease models of NSCLC with NRG1 rearrangements to improve therapy
    Meeting Abstract

    Gladstone, E.; Vojnic, M.; Offin, M.; Delasos, L.; Lui, A.; Siau, E.; Sato, H.; Benayed, R.; Kurth, R.; Mattar, M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in EGFR-mutant non-small cell lung cancer cells
    Meeting Abstract

    Namba, K.; Shien, K.; Takahashi, Y.; Sato, H.; Yoshioka, T.; Suzawa, K.; Yamamoto, H.; Soh, J.; Tomida, S.; Toyooka, S.
    Cancer Research (2019)

    Fulltext@MSK | Save